reviewTop 1% cited

The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

Allergy · 2004 · Vol. 60(3) · pp. 302–308

Jean Bousquet✉(Hôpital Arnaud de Villeneuve)Pedro Cabrera(Hospital Universitario de Gran Canaria Doctor Negrín)Neville Berkman(Hadassah Medical Center)Roland Buhl(Johannes Gutenberg University Mainz)Stephen T. Holgate(Southampton General Hospital)Sally E. Wenzel(University of Colorado Denver)Helen Fox(Novartis (United Kingdom))S. Hedgecock(Novartis (United Kingdom))Martin Blogg(Novartis (United Kingdom))Giovanni Della Cioppa(Novartis (United Kingdom))

View via DOI Publisher page

Abstract

These results suggest that omalizumab may fulfil an important need in patients with severe persistent asthma, many of whom are not adequately controlled on current therapy.

Asthma and respiratory diseases Respiratory and Cough-Related Research Allergic Rhinitis and SensitizationOmalizumabMedicineAsthmaExacerbationImmunoglobulin EPoisson regressionEmergency departmentPlaceboInternal medicineRate ratio

MeSH terms

OmalizumabAntibodies, Anti-IdiotypicAntibodies, MonoclonalAsthmaEmergency Medical ServicesHumansImmunoglobulin ESeverity of Illness IndexRandomized Controlled Trials as TopicAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Citations

399

FWCI

13.07

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

British Guideline on the Management of Asthma